Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
. Pasireotide-LAR is a multireceptor-targeted somatostatin analog with superior clinical efficacy over octreotide-LAR ( 9 ) that can control GH and IGF-1 concentrations in patients resistant to 1gSRL ( 10 ). Consequently, it is approved for treatment of
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
and HbA1c levels are shown in response to octreotide/lanreotide depots and then with pasireotide LAR beginning in 2006, until withdrawn 18 months ago. The normal range for IGF-1 is outlined in grey in the lower part of the graph. The postoperative
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
randomized, open-label, phase IV study . Pituitary 2021 24 887 – 903 . ( https://doi.org/10.1007/s11102-021-01161-4 ) 30 Coopmans EC Muhammad A van der Lely AJ Janssen JAMJL Neggers SJCMM . How to position pasireotide LAR treatment in acromegaly
Search for other papers by Julie M Silverstein in
Google Scholar
PubMed
Biopharmaceuticals Inc, Basking Ridge, NJ, USA), and pasireotide LAR are the currently available SSAs approved by the Food and Drug Administration for the treatment of patients with acromegaly (32, 33, 34, 35) . Approximately 50% of patients with acromegaly achieve
Search for other papers by Antonella Giampietro in
Google Scholar
PubMed
Search for other papers by Sabrina Chiloiro in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Martin Ove Carlsson in
Google Scholar
PubMed
Search for other papers by Francesca Dassie in
Google Scholar
PubMed
Search for other papers by Nunzia Prencipe in
Google Scholar
PubMed
Search for other papers by Marta Ragonese in
Google Scholar
PubMed
Search for other papers by Roy Gomez in
Google Scholar
PubMed
Search for other papers by Simona Granato in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavò in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Pietro Maffei in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
PP Angelini F Liverana L Gessi M Carmelo A , et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response . European Journal of Endocrinology 2021 184 217 – 229 . ( https
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Feng Gu in
Google Scholar
PubMed
Search for other papers by Marcello D Bronstein in
Google Scholar
PubMed
Search for other papers by Thierry C Brue in
Google Scholar
PubMed
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Search for other papers by Shoba Ravichandran in
Google Scholar
PubMed
Search for other papers by Albert Kandra in
Google Scholar
PubMed
Search for other papers by Alberto M Pedroncelli in
Google Scholar
PubMed
Search for other papers by Annamaria A L Colao in
Google Scholar
PubMed
Coculescu M Fleseriu M Guitelman MK Pronin V Raverot G Shimon I Lievre KK et al . Pasireotide LAR demonstrates superior efficacy versus octreotide LAR and lanreotide Autogel in patients with inadequately controlled acromegaly: results from a
Diagnósticos da América SA, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Paula Bruna Araujo in
Google Scholar
PubMed
Neuroendocrinology Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Endocrinology Unit, Hospital Federal de Bonsucesso, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Search for other papers by Carlos Henrique de Azeredo Lima in
Google Scholar
PubMed
Search for other papers by Liana Ogino in
Google Scholar
PubMed
National Cancer Institute, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Aline H S Camacho in
Google Scholar
PubMed
Search for other papers by Leila Chimelli in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Neuroendocrinology Unit, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Rio de Janeiro, Brazil
Search for other papers by Monica R Gadelha in
Google Scholar
PubMed
pituitary surgeries, and the pathology revealed a SG somatotropinoma. Due to resistance to combined first-generation SA and CAB therapy, the patient was started on pasireotide LAR, which resulted in disease control. The missense AIP VUS A299V (c.896C > T
Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed
Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed
Search for other papers by Sally Abbott in
Google Scholar
PubMed
Search for other papers by Tin Chan in
Google Scholar
PubMed
Search for other papers by Sanesh Pillai in
Google Scholar
PubMed
Search for other papers by Kate Maslin in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed
Search for other papers by Barbara McGowan in
Google Scholar
PubMed
Search for other papers by Rob Andrews in
Google Scholar
PubMed
Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed
Search for other papers by Katherine McCullough in
Google Scholar
PubMed
Search for other papers by Lorraine Albon in
Google Scholar
PubMed
Search for other papers by Rachel Batterham in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Shareen Forbes in
Google Scholar
PubMed
Search for other papers by Gavin Bewick in
Google Scholar
PubMed
Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed
-acting SC pasireotide or octreotide (given three times a day before meals) or long-acting IM pasireotide LAR. Moderate 3.3 Diazoxide may be considered as a third-line option if somatostatin analogues are not tolerated. Low 3.4 In people